Integral Molecular announces the mobilization of two of its key technology platforms to aid in the discovery of vaccines and therapeutics against the novel coronavirus which causes COVID-19.
PHILADELPHIA, March 9, 2020 /PRNewswire/ -- Integral Molecular announces the mobilization of two of its key technology platforms to aid in the discovery of vaccines and therapeutics against the novel coronavirus which causes COVID-19. The company will use Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array to understand the human immune response to the virus and identify cellular receptors that explain how the virus has been able to spread so quickly.
Integral Molecular has similarly responded to previous emerging epidemics, including Zika, Ebola and Chikungunya viruses, supporting vaccine and therapeutic discovery efforts throughout industry and academia. The company’s Shotgun Mutagenesis Epitope mapping technology has been used to map over 1,000 antibody binding sites and is used throughout the vaccine industry. The company’s Membrane Proteome Array platform has already been used to identify multiple receptors used by viruses to enter and infect cells.
“Deep expertise in virology is at the core of Integral Molecular’s nearly 20-year history, including our contributions to discovering the receptor for HIV and other viruses,” said Benjamin Doranz, President of Integral Molecular. “We have the ability to use our unique tools to help curb the spread of this deadly virus and have initiated research efforts on multiple fronts to aid in the global effort for a coronavirus vaccine.”
About Integral Molecular
Integral Molecular (www.integralmolecular.com) is the industry leader in epitope mapping and antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and infectious diseases.
Press Contact:
Integral Molecular, Inc.
Soma Banik, PhD, Director of Communications
215-966-6061
info@integralmolecular.com
www.integralmolecular.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/integral-molecular-accelerates-coronavirus-vaccine-research-301019825.html
SOURCE Integral Molecular
